WO2007007076A1 - Solution d'entretien de lentilles de contact - Google Patents

Solution d'entretien de lentilles de contact Download PDF

Info

Publication number
WO2007007076A1
WO2007007076A1 PCT/GB2006/002547 GB2006002547W WO2007007076A1 WO 2007007076 A1 WO2007007076 A1 WO 2007007076A1 GB 2006002547 W GB2006002547 W GB 2006002547W WO 2007007076 A1 WO2007007076 A1 WO 2007007076A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
solution according
contact lens
viscoelastic
range
Prior art date
Application number
PCT/GB2006/002547
Other languages
English (en)
Inventor
David James Lloyd
Original Assignee
Renaissance Healthcare (Europe) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0514118A external-priority patent/GB0514118D0/en
Priority claimed from GB0514505A external-priority patent/GB0514505D0/en
Application filed by Renaissance Healthcare (Europe) Limited filed Critical Renaissance Healthcare (Europe) Limited
Publication of WO2007007076A1 publication Critical patent/WO2007007076A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
    • A61L12/124—Hydrogen peroxide; Peroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005—Other compounding ingredients characterised by their effect
    • C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/22—Carbohydrates or derivatives thereof
    • C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin

Definitions

  • This invention relates to a contact lens care solution, for example a multipurpose solution (particularly one which serves the purposes of preserving, disinfecting, cleaning, lubricating and rinsing) or a hydrogen peroxide neutralizing solution.
  • Hyaluronan is a linear polysaccharide composed of repeating disaccharide units
  • Hyaluronan is an essential component of many extracellular matrices in mature tissues. In some cases hyaluronan is a major constituent, e.g. in the vitreous of the human eye (0.1-0.4 mg/g wet weight) and in the synovial joint fluid (3-4mg/ml).
  • hyaluronan The largest amount of hyaluronan (7-8 g per average adult human, ⁇ 50% of the total in the body) resides in skin tissue, where it is present in both the dermis (0.5 mg/g wet tissue) and the epidermis ( ⁇ 0.1 mg/g wet tissue).
  • rooster combs which contain the polymer at a higher concentration with respect to other animal tissues.
  • biofermentation which utilises micro-organisms to provide extracellular quantities.
  • the study of the physiological role of hyaluronan has led to the development of specific proprietary products, based on different molecular weight profiles for use in orthopaedics, rheumatology, ophthalmology and dermatology.
  • High molecular weight hylauronan at high concentrations in solution can form entangled molecular networks through stearic interactions and self-association between and within individual molecules. The latter can occur when a stretch of the hydrophobic face of the ribbon structure of the backbone interacts reversibly with the hydrophobic face on a comparable stretch of hyaluronan on another molecule or in a different region of the same molecule.
  • Such networks exhibit different properties than would isolated hyaluronan molecules. They can resist rapid, short-duration, fluid flow through the network, thereby exhibiting elastic properties that can distribute load or shear forces within the network. On the other hand, slow fluid flow of longer duration can partially separate and align the molecules, allowing their movement and thereby exhibiting viscous properties.
  • Fluid rheology is used to describe the consistency of products, normally by the two components viscosity and elasticity. Viscosity is usually described as resistance to flow or thickness, and elasticity as stickiness or structure. Fluids are normally divided into three different groups according to their flow characteristics:
  • the viscosity ( ⁇ ) of a Newtonian fluid is dependent only on temperature and not on
  • time-dependent non-Newtonian fluid is dependent not only on temperature but also on shear rate. Depending on how viscosity changes with shear rate.the flow behaviour of a time- independent non-Newtonian fluid is characterised as:
  • Shear thinning materials are also called pseudoplastic, e.g. paint and shampoo, and shear thickening fluids are also called dilatants, e.g. starch suspensions.
  • plastic fluids include toothpaste.
  • For a time dependent non-Newtonian fluid the viscosity of the fluid is dependent on temperature, shear rate and time. A Newtonian fluid will exhibit a linear relationship between shear stress a shear rate and hence viscosity is independent of the applied shear conditions. A no Newtonian fluid, on the other hand, does not exhibit such a relationship.
  • the me common form of non-Newtonian flow is shear thinning or pseudoplasticity (a decrease viscosity with increasing shear) and is seen in most complex fluids, e.g. colloids, g ⁇ and solutions.
  • Tl length of the zero shear viscosity plateau is inversely proportional to the molecul weight distribution, i.e. the shorter the plateau and the greater the polydispersity inde the more polydisperse the material.
  • the polydispersity index ( PDI) is a measure of the distribution of molecular weights in a given polymer sample.
  • the PDI is calculated as the weight-average molecular weight divided by the number average molecular weight. As the polymer chains approach uniform chain length, the PDI approaches unity (1).
  • weight average molecular weight (M (w)) is a way of describing the molecular weight of a polymer and the number average molecular weight (M (n)) is a
  • Viscoelastic exhibits viscous as well as elastic behaviour
  • viscoelastic materials are artificial or natural gels. Normally, however, the term “viscous” is used for fluids with high viscosity. In most cases of viscoelastic behaviour the time factor has significant impact on the flow properties observed.
  • Creep is an ideal technique for measuring viscoelastic structure in materials, and can simulate many real-time, real-life processes and situations, e.g. sedimentation (gravity driven).
  • a creep test a small, constant stress is applied to a sample until the rate of change of shear is constant (the retardation step), and the resulting deformation is monitored throughout. It is usual then to remove the stress, and to monitor the rate at which and extent to which the sample recovers its original dimensions (the relaxation step).
  • An elastic solid can be modelled by a spring which will deform when a uniform stress is applied. This stress-induced deformation will recover its original dimensions once the stress is removed. Elasticity can therefore be defined as reversible stress behaviour.
  • the material will typically have initially an elastic property, later a viscoelastic property, and finally an entirely viscous property.
  • Certain multipurpose solutions contain viscosity enhancing agents such as celluloses, e.g. hydroxypropylmethylcellulose (hypromellose) and claims are made that these also condition lenses to create a shield of protection between the lens and the eye.
  • Hypromellose typically follows the flow behaviour of Newtonian fluids.
  • Properties of cellulose type additives to contact lens care solutions have been known for over 40 years; in particular they were added to contact lens wetting solutions for use with polymethylmethacrylic acid (PMMA) and rigid gas permeable (RGP) contact lenses.
  • PMMA polymethylmethacrylic acid
  • RGP rigid gas permeable
  • the contact lens care solution will normally be a multipurpose solution, a hydrogen peroxide neutralizing solution, or a rinsing solution.
  • Contact lens care solutions that would particularly benefit from containing viscoelastic polysaccharide include multipurpose solutions, the purposes of which comprise the disinfecting, preserving, cleaning, lubricating and rinsing of all types of contact lenses, and hydrogen peroxide neutralising solutions used in two-stage hydrogen peroxide disinfecting regimes.
  • Two- stage hydrogen peroxide regimes provide a first stage in which the hydrogen peroxide is anti-microbially active and a second stage in which the hydrogen peroxide is neutralised in readiness for insertion of the contact lens into the eye.
  • the viscoelastic polysaccharide is advantageously in a proportion of between 0.01% and 2.0% w/v of the care solution, with a molecular weight (MDa-Megadaltons) of 0.1MDa to 3.5MDa .
  • An embodiment of the present invention is the inclusion in a contact lens care solution of one or more of the group consisting of hyaluronan, its salts and chondroitin sulphate.
  • hyaluronan its salts and chondroitin sulphate.
  • contact lens wearers regard comfort, both on initial insertion of the contact lens and during wear, particularly towards the end of the wearing day, as the most important prerequisite when using contact lens care solutions in association with contact lenses. This has become increasingly important since the advent of two-stage hydrogen peroxide disinfecting regimes in the early 1980s and latterly multipurpose solutions.
  • the present inventor was surprised to discover that the molecular weight distribution (or polydispersity) of a sample of hyaluronan had a significant influence on the desired physical properties or optimum subjective characteristics required for contact lens care solutions.
  • This embodiment takes advantage of his discovery that hyaluronan, for example, will provide the necessary comfort during contact lens wear (as mentioned above) using a typical molecular weight range of 0.1MDa to 3.5MDa but a significant improvement in comfort is obtained by using hyaluronan within that typical molecular weight range, but with a very narrow molecular weight distribution.
  • the polydispersity of the hyaluronan used to provide optimum comfort for contact lens wearers falls within a very narrow molecular weight range.
  • the PDI is a very important characteristic with respect to a viscoelastic material used in the formulation of contact lens care products.
  • an important aspect of this invention is to select a viscoelastic material with a PDI of ⁇ 3, preferably ⁇ 2, but particularly between 1.2 and 1.6.
  • any selected molecular weight of a viscoelastic material in the range 0.1 MDa to 3.5 MDa used in a contact lens care product will have a PDI preferably between 1.2 and 1.6 as depicted in the accompanying diagrammatic Figures 2 and 3.
  • hyaluronan to retain a very large weight of water relative to its own weight, a prerequisite for lubricity, and its muco-adhesive ability giving improved retention times in the eye, offer a significant improvement over traditional wetting agents, for example, celluloses, polyvinyl acetate and polyvinylpyrrolidine, to name but a few.
  • traditional wetting agents for example, celluloses, polyvinyl acetate and polyvinylpyrrolidine, to name but a few.
  • the contact lens care solution may contain one or more cationic preservatives and, in particular, one or more polycationic preservatives in a range between 0.05 and 5.0 ppm and a mixture of non- ionic and/or amphoteric surfactants (0.001% to 10% w/v).
  • the solution may contain one or more tonicity adjusting agents, for example an inorganic tonicity adjusting agent such as sodium chloride or, more preferably, one or more non-ionic organic tonicity adjusting agents such as polyhydric alcohols, for example, propylene glycol, glycerol, glucose, lactose, mannitol, and sorbitol, and glycine and urea; one or more buffering agents, for example phosphates, borates, carbonates, bicarbonates, citrates, phthalates, oxalates, acetates, and amines; and one or more chelating agents, e.g. ethylenediaminetetraacetic acid (EDTA).
  • EDTA ethylenediaminetetraacetic acid
  • a preferred combination of tonicity adjusting agent, buffering agent and chelating agent is the use of sorbitol, phosphate buffer and disodium edetate, respectively.
  • 3.5MDa are selected from the group consisting of hyaluronan, its salts, and chondroitin sulphate, in a range of 0.01% to 2.0 %w/v, preferably 0.05% to 0.5% w/v, but more preferably 0.05% to 0.2% w/v of the solution.
  • the selected polysaccharide is compatible with all types of contact lenses since it does not adsorb to the contact lens surface and thus does not absorb into the contact lens matrix and therefore does not change the optical parameters of the contact lens.
  • the contact lens care solution includes in the contact lens care solution one or more physiologically acceptable amphoteric surfactants and/or non-ionic surfactants, either in combination or alone, to provide a cleaning function.
  • concentration of the surfactant or of the mixture of surfactants is in the range of 0.001% to 10% w/v, preferably 0.05% to 5% w/v, but more preferably 0.05% to 1.0% w/v of the solution.
  • non-ionic surfactants examples include ethylene oxide propylene oxide block copolymers and tetra (polyoxyethylene-co-polypropylene) ethylenediamine (poloxamers and poloxamines), ethers of fatty alcohols and of oligosaccharides (such as for instance the alkyl polyglycosides known under the name "Triton"), esters of fatty acids and sorbitan, esters of fatty acids with polyoxyethylene, esters of alkylphenoles and polyoxyethylene.
  • polysorbates such as Tween 80 (i.e. polysorbate 80), and poloxamers such as pluronic 127 (i.e.
  • amphoteric surfactants include coconut oil, which is a mixture of lauric, myristic, oleic, stearic, palmitic and other similar acids; lauric acid; capric acid; caprylic acid and ethylhexoic acid mixtures; oleic acid; linoleic and tearic acid.
  • ionised amphoteric salts such as Miranol 2MCA and Miranol C2M and cocoamidopropyl betaine.
  • amphoteric or non-ionic surfactants to ophthalmic formulations is widely used because of their limited aggressiveness compared with anionic surfactants. However, they have been reported to cause corneal staining. Moreover, polycationic preservatives such as polyhexamethylene biguanide, chlorhexidine acetate, chlorhexidine gluconate and bezalkonium chloride, have also been reported as causing corneal staining, whilst the inclusion of both polycationic preservative and amphoteric or non-ionic surfactant is reported to produce more severe corneal staining.
  • a further advantage of the addition of a viscoelastic agent to the care solution is that the inclusion of one or both of a polycationic preservative and an amphoteric or non-ionic surfactant can be surprisingly well tolerated, to the extent that corneal staining can be eliminated or substantially reduced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Eyeglasses (AREA)
  • Detergent Compositions (AREA)

Abstract

L'invention concerne une solution d'entretien de lentilles de contact sous la forme d'une solution multifonctionnelle ou d'une solution de neutralisation à base de peroxyde d'hydrogène contenant un polysaccharide viscoélastique dans une proportion allant de 0,01 % à 2,0 % p/v de la solution, avec un poids moléculaire allant de 0,1 (MDa-Megadalton) à 3,5 MDa et un (indice de polymolécularité) PDI <3. Cela permet d'exploiter pleinement les propriétés physico-chimiques des polysaccharides viscoélastiques, tels que le hyaluronane, et cela en fait des candidats idéaux comme agents destinés à améliorer le confort des formulations de solutions d'entretien de lentilles de contact.
PCT/GB2006/002547 2005-07-09 2006-07-10 Solution d'entretien de lentilles de contact WO2007007076A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0514118.9 2005-07-09
GB0514118A GB0514118D0 (en) 2005-07-09 2005-07-09 Improvements in or relating to contact lens care products
GB0514505A GB0514505D0 (en) 2005-07-14 2005-07-14 Improvements in or relating to contact lens care products
GB0514505.7 2005-07-14

Publications (1)

Publication Number Publication Date
WO2007007076A1 true WO2007007076A1 (fr) 2007-01-18

Family

ID=37103115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002547 WO2007007076A1 (fr) 2005-07-09 2006-07-10 Solution d'entretien de lentilles de contact

Country Status (1)

Country Link
WO (1) WO2007007076A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017058453A (ja) * 2015-09-15 2017-03-23 株式会社メニコン コンタクトレンズ用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259202A (en) * 1979-02-27 1981-03-31 Toyo Contact Lens Co., Ltd. Cleaning and preservative solution for contact lenses
WO2000060038A1 (fr) * 1999-04-02 2000-10-12 Laboratoire Medidom S.A. Solution ophtalmique a viscosite amelioree ayant une action detergente sur des lentilles de contact
EP1473584A1 (fr) * 2002-02-07 2004-11-03 Ophtecs Corporation Solution pour lentilles de contact

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259202A (en) * 1979-02-27 1981-03-31 Toyo Contact Lens Co., Ltd. Cleaning and preservative solution for contact lenses
WO2000060038A1 (fr) * 1999-04-02 2000-10-12 Laboratoire Medidom S.A. Solution ophtalmique a viscosite amelioree ayant une action detergente sur des lentilles de contact
EP1473584A1 (fr) * 2002-02-07 2004-11-03 Ophtecs Corporation Solution pour lentilles de contact

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017058453A (ja) * 2015-09-15 2017-03-23 株式会社メニコン コンタクトレンズ用組成物

Similar Documents

Publication Publication Date Title
CA2565944C (fr) Preparations de hyaluronane stabilise et methodes correspondantes
US8501822B2 (en) Ophthalmic composition containing alginic acid or salt thereof
US20060052340A1 (en) Ophthalmic solution
US20090036554A1 (en) Ophthalmic compositions comprising a terpene compound
JP6871334B2 (ja) コンタクトレンズ用組成物およびそれを用いたコンタクトレンズパッケージ
JP5616619B2 (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
CN105188779B (zh) 天然蜡的聚(氮/胺)衍生物和眼用组合物
JP4850513B2 (ja) 点眼用組成物
CN112094582A (zh) 能增加湿润感的隐形眼镜溶液及包含其的隐形眼镜产品
JP4976607B2 (ja) コンタクトレンズ用ゲル状洗浄剤
JP2011136988A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
KR20230156748A (ko) 안과 용액
CN109722347B (zh) 一种含有黄原胶的保湿润滑组合物及其应用
JP2008209677A (ja) 殺菌剤不活化液剤
CA2736380A1 (fr) Compositions comprenant des polymeres ayant des motifs d&#39;osamine et procedes de fabrication et d&#39;utilisation de ceux-ci
WO2007007076A1 (fr) Solution d&#39;entretien de lentilles de contact
ES2652268T3 (es) Reducción al mínimo de los depósitos biológicos de lípidos que hay sobre las lentes de contacto
CN1389213A (zh) 一种润眼液组合物及其应用
JP5080418B2 (ja) コンタクトレンズ用溶液
WO2013103830A1 (fr) Procédés et trousses permettant d&#39;étendre l&#39;utilisation de lentilles de contact
WO2005023283A1 (fr) Composition ophtalmique
JP2023111965A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
TW202206583A (zh) 隱形眼鏡用溶液及其利用
JP5689198B2 (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
JP2018197272A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06764916

Country of ref document: EP

Kind code of ref document: A1